Article Supporting Oncosil Trial

I am new to this stock and just come across this article published 13 January 2021 by doctor's from Adelaide.

https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1353-0941

The article conclusion and support from the doctor's is very promising considering TGA decision may come anytime over coming weeks... IMO.

Providing abstract from the article for reference as not sure if it was provided by company before. I am not a doctor or scientist but result highlighted below is promising and if approved by TGA then it holds more hopes to the patients... IMO.

Just note that the article below is good enough for me to invest in this company as achieving in R0 in 4 out 12 itself is promising result IMHO.

Abstract

BackgroundThis study evaluated clinical outcomes of combined chemotherapy and endoscopic ultrasound (EUS)-guided intratumoral radioactive phosphorus-32 (³²P) implantation in locally advanced pancreatic adenocarcinoma (LAPC).

MethodsConsecutive patients with newly diagnosed LAPC were recruited over 20 months. Baseline computed tomography and¹⁸F-2-fluoro-2-deoxy-D-glucose (¹⁸FDG) positron emission tomography–computed tomography were performed and repeated after 12 weeks to assess treatment response. Following two cycles of conventional chemotherapy, patients underwent EUS-guided³²P implantation followed by six chemotherapy cycles.

Results12 patients with LAPC (median age 69 years [interquartile range 61.5–73.3]; 8 male) completed treatment. Technical success was 100 % with no procedural complications. At 12 weeks, median reduction in tumor volume was 8.2 cm³ (95 % confidence interval 4.95–10.85;P = 0.003), with minimal or no¹⁸FDG uptake in nine patients (75 %). Tumor downstaging was achieved in six patients (50 %), leading to successful resection in five (42 %), including four R0 resections (80 %).

Conclusions EUS-guided³²P implantation was feasible, well tolerated, and resulted in a 42 % surgical resection rate. Further evaluation in a larger randomized multicenter trial is warranted.

Author Affiliations

Jeevinesh Naidu 

¹Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia

²School of Health and Medical Sciences, University of Adelaide, Adelaide, Australia

Dylan Bartholomeusz

¹Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia

²School of Health and Medical Sciences, University of Adelaide, Adelaide, Australia

³Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, Australia

Joshua Zobel

¹Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia

Romina Safaeian

¹Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia

William Hsieh

³Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, Australia

Benjamin Crouch

³Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, Australia

Karen Ho

³Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, Australia

Deborah Calnan

³Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, Australia

Nimit Singhal

⁴Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia

Andrew Ruszkiewicz

²School of Health and Medical Sciences, University of Adelaide, Adelaide, Australia

⁵Department of Pathology, Royal Adelaide Hospital, Adelaide, Australia

John W. Chen

⁶Department of Hepatobiliary Surgery, Royal Adelaide Hospital, Adelaide, Australia

Chuan Ping Tan

⁶Department of Hepatobiliary Surgery, Royal Adelaide Hospital, Adelaide, Australia

Paul Dolan

⁶Department of Hepatobiliary Surgery, Royal Adelaide Hospital, Adelaide, Australia

Nam Q. Nguyen

¹Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia

²School of Health and Medical Sciences, University of Adelaide, Adelaide, Australia


GLAH, DYOR